Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

For many years, we have been using beta-blockers to neutralise a specific stress hormone and prevent dangerous heart rhythms following a heart attack. However, a new study led Department of Physiology, Anatomy & Genetics (DPAG) and published in the European Heart Journal has uncovered evidence for an additional stress hormone acting as a key trigger for dangerous heart rhythms that is not currently targeted by these drugs.

© Shutterstock

Cardiovascular disease is the main cause of death in the UK and throughout the Western World. Around half of these are caused by an unexpected change in the rhythm of the heart leading to collapse and cardiac arrest, known as "sudden cardiac death." The most common trigger for this is a heart attack, which occurs when one of the heart's arteries is blocked. However, why some heart attacks trigger dangerous heart rhythms and others do not is not fully understood.

Introduced over 50 years ago, drugs called beta-blockers stop the action of a stress hormone called norepinephrine, and are currently the only drugs that prolong life after a heart attack by helping to prevent dangerous heart rhythms. In new research from the DPAG, it is hypothesised that an additional stress hormone called Neuropeptide-Y (NPY) may be a key trigger for dangerous heart rhythms. 

Read more (Department of Physiology, Anatomy & Genetics)

Similar stories

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.

Cathy Creswell, David Roberts, and Matthew Costa elected Fellows of Academy of Medical Sciences

Cathy Creswell, Professor of Developmental Clinical Psychology at the Departments of Psychiatry and Experimental Psychology, David Roberts, Professor of Haematology at the Radcliffe Department of Medicine and Consultant Haematologist, and Matthew Costa, Professor of Orthopaedic Trauma Surgery at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, have been elected Fellows of the Academy of Medical Sciences.